Cisplatin/etoposide vs paclitaxel/cisplatin/G-CSF vs paclitaxel/cisplatin in non-small-cell lung cancer

P. Bonomi, K. Kim, J. Kusler, D. Johnson

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

A phase III trial conducted b) Eastern Cooperative Oncology Group (ECOG) investigators assessed the possible impact of paclitaxel on survival, response, and toxicity in patients with advanced non-small-cell lung cancer. Three regimens were compared: cisplatin/etoposide, paclitaxel/cisplatin/granulocyte colony-stimulating factor (G-CSF), and paclitaxel/cisplatin. Patients were randomly assigned to the regimens, each of which was repeated every 21 days over a 17-month period. Response rates were 12% in the cisplatin/etoposide group, 31% in the paclitaxel/cisplatin/GCSF group, and 26% in the paclitaxel/cisplatin group. Significant differences in response were observed between the cisplatin/etoposide and paclitaxel/cisplatin/G-CSF groups and the cisplatin/etoposide and paclitaxel/cisplatin groups; there was no significant difference between patients treated with paclitaxel/cisplatin vs paclitaxel/cisplatin/G-CSF. Both paclitaxel regimens were associated with significantly higher response rates compared with etoposide/cisplatin. Based on preliminary survival analyses, the investigators concluded that the paclitaxel regimens may be associated with superior survival.

Original languageEnglish (US)
Pages (from-to)9-10
Number of pages2
JournalOncology
Volume11
Issue number4 SUPPL. 3
StatePublished - 1997

Fingerprint

Granulocyte Colony-Stimulating Factor
Etoposide
Non-Small Cell Lung Carcinoma
Cisplatin
Paclitaxel
Research Personnel
Survival
TP protocol
Survival Analysis

ASJC Scopus subject areas

  • Oncology

Cite this

Cisplatin/etoposide vs paclitaxel/cisplatin/G-CSF vs paclitaxel/cisplatin in non-small-cell lung cancer. / Bonomi, P.; Kim, K.; Kusler, J.; Johnson, D.

In: Oncology, Vol. 11, No. 4 SUPPL. 3, 1997, p. 9-10.

Research output: Contribution to journalArticle

Bonomi, P. ; Kim, K. ; Kusler, J. ; Johnson, D. / Cisplatin/etoposide vs paclitaxel/cisplatin/G-CSF vs paclitaxel/cisplatin in non-small-cell lung cancer. In: Oncology. 1997 ; Vol. 11, No. 4 SUPPL. 3. pp. 9-10.
@article{92d8f1a8f2f44d88918d957e9c82184b,
title = "Cisplatin/etoposide vs paclitaxel/cisplatin/G-CSF vs paclitaxel/cisplatin in non-small-cell lung cancer",
abstract = "A phase III trial conducted b) Eastern Cooperative Oncology Group (ECOG) investigators assessed the possible impact of paclitaxel on survival, response, and toxicity in patients with advanced non-small-cell lung cancer. Three regimens were compared: cisplatin/etoposide, paclitaxel/cisplatin/granulocyte colony-stimulating factor (G-CSF), and paclitaxel/cisplatin. Patients were randomly assigned to the regimens, each of which was repeated every 21 days over a 17-month period. Response rates were 12{\%} in the cisplatin/etoposide group, 31{\%} in the paclitaxel/cisplatin/GCSF group, and 26{\%} in the paclitaxel/cisplatin group. Significant differences in response were observed between the cisplatin/etoposide and paclitaxel/cisplatin/G-CSF groups and the cisplatin/etoposide and paclitaxel/cisplatin groups; there was no significant difference between patients treated with paclitaxel/cisplatin vs paclitaxel/cisplatin/G-CSF. Both paclitaxel regimens were associated with significantly higher response rates compared with etoposide/cisplatin. Based on preliminary survival analyses, the investigators concluded that the paclitaxel regimens may be associated with superior survival.",
author = "P. Bonomi and K. Kim and J. Kusler and D. Johnson",
year = "1997",
language = "English (US)",
volume = "11",
pages = "9--10",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "4 SUPPL. 3",

}

TY - JOUR

T1 - Cisplatin/etoposide vs paclitaxel/cisplatin/G-CSF vs paclitaxel/cisplatin in non-small-cell lung cancer

AU - Bonomi, P.

AU - Kim, K.

AU - Kusler, J.

AU - Johnson, D.

PY - 1997

Y1 - 1997

N2 - A phase III trial conducted b) Eastern Cooperative Oncology Group (ECOG) investigators assessed the possible impact of paclitaxel on survival, response, and toxicity in patients with advanced non-small-cell lung cancer. Three regimens were compared: cisplatin/etoposide, paclitaxel/cisplatin/granulocyte colony-stimulating factor (G-CSF), and paclitaxel/cisplatin. Patients were randomly assigned to the regimens, each of which was repeated every 21 days over a 17-month period. Response rates were 12% in the cisplatin/etoposide group, 31% in the paclitaxel/cisplatin/GCSF group, and 26% in the paclitaxel/cisplatin group. Significant differences in response were observed between the cisplatin/etoposide and paclitaxel/cisplatin/G-CSF groups and the cisplatin/etoposide and paclitaxel/cisplatin groups; there was no significant difference between patients treated with paclitaxel/cisplatin vs paclitaxel/cisplatin/G-CSF. Both paclitaxel regimens were associated with significantly higher response rates compared with etoposide/cisplatin. Based on preliminary survival analyses, the investigators concluded that the paclitaxel regimens may be associated with superior survival.

AB - A phase III trial conducted b) Eastern Cooperative Oncology Group (ECOG) investigators assessed the possible impact of paclitaxel on survival, response, and toxicity in patients with advanced non-small-cell lung cancer. Three regimens were compared: cisplatin/etoposide, paclitaxel/cisplatin/granulocyte colony-stimulating factor (G-CSF), and paclitaxel/cisplatin. Patients were randomly assigned to the regimens, each of which was repeated every 21 days over a 17-month period. Response rates were 12% in the cisplatin/etoposide group, 31% in the paclitaxel/cisplatin/GCSF group, and 26% in the paclitaxel/cisplatin group. Significant differences in response were observed between the cisplatin/etoposide and paclitaxel/cisplatin/G-CSF groups and the cisplatin/etoposide and paclitaxel/cisplatin groups; there was no significant difference between patients treated with paclitaxel/cisplatin vs paclitaxel/cisplatin/G-CSF. Both paclitaxel regimens were associated with significantly higher response rates compared with etoposide/cisplatin. Based on preliminary survival analyses, the investigators concluded that the paclitaxel regimens may be associated with superior survival.

UR - http://www.scopus.com/inward/record.url?scp=0030760987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030760987&partnerID=8YFLogxK

M3 - Article

C2 - 9144683

AN - SCOPUS:0030760987

VL - 11

SP - 9

EP - 10

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 4 SUPPL. 3

ER -